Health Economics›Chronic myeloid leukemia›Chronic phase first-line therapy

Chronic phase first-line therapy

Chronic myeloid leukemia · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Asciminib monotherapy Variant #01	—	R 199 106	28d	—	—	~2	~R 398 211 indirect	—
Nilotinib monotherapy Variant #01	—	R 28 002	28d	—	—	~2	~R 56 004 indirect	—
Dasatinib monotherapy Variant #01	—	R 12 899	28d	—	—	~2	~R 25 797 indirect	—
Busulfan monotherapy Variant #01	—	R 9 802	28d	—	—	~2	~R 19 604 indirect	—
Imatinib and LoDAC Variant #01	—	R 6 227	28d	—	—	~14	~R 87 179 indirect	—
Imatinib monotherapy Variant #16	—	R 1 401	28d	~20.0 mo	~53.0 mo	~2	~R 2 801 PFS proxy · indirect	8
Imatinib and Interferon alfa Variant #01 Partial	—	R 1 401	7d	—	—	~8	~R 11 206 indirect	—
Imatinib and Peginterferon alfa-2a Variant #01 Partial	—	R 1 401	7d	—	—	~2	~R 2 801 indirect	—
Hydroxyurea and Interferon alfa-2a Variant #01 Partial	—	R 741	28d	—	—	~2	~R 1 481 indirect	—
Cytarabine and Interferon alfa-2b Variant #01 Partial	—	R 446	30d	—	—	2	R 892 PFS proxy	1
Hydroxyurea monotherapy Variant #01	—	R 265	28d	—	~243.6 mo	~2	~R 529 PFS proxy · indirect	—
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	~5.4 mo	~17.5 mo	~2	—	10
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	—	—	48	—	1
Radotinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Interferon alfa-n1 monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
Interferon alfa monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Bosutinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

17 of 17 regimens shown